Nikolaus Lubomierski

Author

Goethe University Frankfurt

Also Known As

Andrea Frilling, N Lubomierski, N. Lubomierski, NIKOLAUS LUBOMIERSKI, Nikolaus Lubomierski

Publications

361

Citations

H-Index

Concepts

All Affiliations

Goethe University Frankfurt University Hospital Ulm Philipps University of Marburg University Hospital Frankfurt

About

Nikolaus Lubomierski is an author at Goethe University Frankfurt specializing in cancer research, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	247
2	Cell Biology	2	2	100
3	Health Sciences	1	1	13
4	Natural Sciences	1	1	25
5	Hepatology	1	1	13

Nikolaus Lubomierski

Publications

332

Citations

H-Index

Page 1

	Year	Citations
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme Markus Moehler, Annett Maderer, C Schimanski, European Journal of Cancer UrologyGastrointestinal OncologyMedicineBiliary CancerSorafenib Versus Gemcitabine	2014	134
Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Nikolaus Lubomierski, Michael Kersting, Tillmann Bert, PubMed PathologyFunctional InactivationCancer BiologyGliomaTumor Biology	2001	75
<i>BRAF</i> mutations in colorectal carcinoma suggest two entities of microsatellite‐unstable tumors Nikolaus Lubomierski, Guido Plotz, Marc Wormek, Cancer	2005	70
Expression spectrum and methylation-dependent regulation of melanoma antigen-encoding gene family members in pancreatic cancer cells Tillmann Bert, Nikolaus Lubomierski, Susanne Gangsauge, Pancreatology Tumor BiologyMethylation-dependent RegulationSystems BiologyPancreatic CancerEpigenetic Regulation	2002	25
Efficacy and Safety of Sorafenib in Advanced Hepatocellular Carcinoma Under Daily Practice Conditions Martin‐Walter Welker, Nikolaus Lubomierski, C. Gog, Journal of Chemotherapy	2010	15
A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data. Markus Moehler, Carl Christoph Schimanski, S Kanzler, Journal of Clinical Oncology MultimodalityPharmacotherapySorafenib Versus GemcitabineOncologyGastrointestinal Oncology	2011	13

Page 1